 NEW YORK and LONDON, July 07, 2021 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX Akari or the Company, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, today announced that it has entered into definitive securities purchase agreements with certain accredited and institutional investors, led by existing investors of the Company, including Dr. Ray Prudo, the Companys Chairman, to receive gross proceeds of approximately 12 million through a private placement of its equity securities. 